CRDF

MKT CAP:$117M

Cardiff Oncology, Inc.

Market Cap

$117M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$1.67-$0.99 (-37.22%)

Apr 23, 2026

Company Details

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; C...

CEO

Mani Mohindru

IPO Date

Jul 27, 2004

Website

www.cardiffoncology.com

Key Metrics TTM

Revenue

$593.0K

-13.3% YoY

Net Income

-$46M

EPS (Diluted)

-$0.77

Free Cash Flow

-$38M

Revenue / Share

$0.01

Gross Margin

-1890.4%

Operating Margin

-8256.3%

Net Margin

-7732.2%

FCF Margin

-6402.5%

P/S

196.6x

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Feb 24, 2026

$593.0K-13.2%EPS -$0.69

Q4 2025

Feb 24, 2026

$243.0K+60.9%EPS -$0.11

Q3 2025

Nov 6, 2025

$120.0K-27.3%EPS -$0.17

Q2 2025

Jul 29, 2025

$121.0K-25.8%EPS -$0.21

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$74.0K	$74.0K	-$11M
Q2 22	$91.0K	$91.0K	-$10M
Q3 22	$93.0K	$93.0K	-$9M
Q4 22	$128.0K	$128.0K	-$9M
Q1 23	$83.0K	$83.0K	-$12M
Q2 23	$108.0K	$108.0K	-$12M
Q3 23	$141.0K	$34.0K	-$11M
Q4 23	$156.0K	$53.0K	-$10M
Q1 24	$205.0K	$103.0K	-$11M
Q2 24	$163.0K	$58.0K	-$13M
Q3 24	$165.0K	-$9M	-$13M
Q4 24	$151.0K	$151.0K	-$13M
Q1 25	$109.0K	$109.0K	-$14M
Q2 25	$121.0K	-$11M	-$15M
Q3 25	$120.0K	$120.0K	-$12M
Q4 25	$243.0K	$20.0K	-$8M

Valuation

Quarter	P/S	P/E
Q1 22	322.9x	—
Q2 22	303.5x	—
Q3 22	298.1x	—
Q4 22	302.0x	—
Q1 23	295.1x	—
Q2 23	282.9x	—
Q3 23	253.4x	—
Q4 23	238.9x	—
Q1 24	191.1x	—
Q2 24	175.3x	—
Q3 24	169.2x	—
Q4 24	170.4x	—
Q1 25	198.2x	—
Q2 25	213.5x	—
Q3 25	232.7x	—
Q4 25	196.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$10M	-$10M
Q2 22	-$7M	-$7M
Q3 22	-$7M	-$8M
Q4 22	-$9M	-$9M
Q1 23	-$9M	-$9M
Q2 23	-$7M	-$7M
Q3 23	-$8M	-$8M
Q4 23	-$7M	-$7M
Q1 24	-$8M	-$8M
Q2 24	-$9M	-$9M
Q3 24	-$10M	-$10M
Q4 24	-$10M	-$10M
Q1 25	-$13M	-$13M
Q2 25	-$8M	-$8M
Q3 25	-$11M	-$11M
Q4 25	-$6M	-$6M

Capital Expenditures

Quarter	CapEx
Q1 22	$171.0K
Q2 22	$312.0K
Q3 22	$448.0K
Q4 22	$75.0K
Q1 23	$8.0K
Q2 23	$251.0K
Q3 23	$315.0K
Q4 23	$8.0K
Q1 24	$80.0K
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$26.0K
Q3 25	$18.0K
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+2.8%	+102.2%
Q2 22	+33.8%	+51.4%
Q3 22	+8.1%	+28.3%
Q4 22	-3.8%	-1.4%
Q1 23	+12.2%	+8.9%
Q2 23	+18.7%	+16.9%
Q3 23	+51.6%	+20.6%
Q4 23	+21.9%	+10.2%
Q1 24	+147.0%	-8.2%
Q2 24	+50.9%	+3.2%
Q3 24	+17.0%	+16.5%
Q4 24	-3.2%	+21.3%
Q1 25	-46.8%	+30.1%
Q2 25	-25.8%	+17.2%
Q3 25	-27.3%	-5.3%
Q4 25	+60.9%	-36.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$1M	1556.8%
Q2 22	$1M	1159.3%
Q3 22	$1M	1115.1%
Q4 22	$1M	790.6%
Q1 23	$1M	1281.9%
Q2 23	$2M	1463.9%
Q3 23	$955.0K	677.3%
Q4 23	$909.0K	582.7%
Q1 24	$1M	548.3%
Q2 24	$1M	723.3%
Q3 24	$1M	759.4%
Q4 24	$1M	797.4%
Q1 25	$1M	1252.3%
Q2 25	$2M	1390.9%
Q3 25	$1M	1153.3%
Q4 25	$1M	518.9%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 22	$7M	$4M	—
Q2 22	$7M	$2M	$692.0K
Q3 22	$6M	$2M	$678.0K
Q4 22	$6M	$5M	—
Q1 23	$9M	$3M	—
Q2 23	$8M	$4M	$584.0K
Q3 23	$8M	$2M	$536.0K
Q4 23	$8M	$4M	—
Q1 24	$8M	$3M	—
Q2 24	$9M	$3M	$459.0K
Q3 24	$10M	—	—
Q4 24	$10M	$3M	—
Q1 25	$10M	$4M	—
Q2 25	$12M	—	—
Q3 25	$8M	$4M	—
Q4 25	$5M	$3M	—

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$20M	$109M	$129M
Q2 22	$21M	$101M	$122M
Q3 22	$19M	$96M	$114M
Q4 22	$16M	$89M	$105M
Q1 23	$15M	$82M	$97M
Q2 23	$19M	$70M	$89M
Q3 23	$15M	$66M	$81M
Q4 23	$22M	$53M	$75M
Q1 24	$19M	$49M	$67M
Q2 24	$26M	$35M	$60M
Q3 24	$13M	$45M	$58M
Q4 24	$51M	$40M	$92M
Q1 25	$24M	$56M	$80M
Q2 25	$11M	$60M	$71M
Q3 25	$10M	$50M	$61M
Q4 25	$17M	$41M	$58M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	43M	+6.5%	+16.3%
Q2 22	43M	+0.2%	+11.7%
Q3 22	43M	+0.1%	+9.6%
Q4 22	45M	+3.1%	+10.0%
Q1 23	45M	0.0%	+3.3%
Q2 23	45M	0.0%	+3.2%
Q3 23	45M	0.0%	+3.1%
Q4 23	45M	0.0%	0.0%
Q1 24	45M	+0.0%	+0.0%
Q2 24	45M	+0.3%	+0.3%
Q3 24	47M	+4.6%	+4.9%
Q4 24	48M	+1.7%	+6.7%
Q1 25	48M	0.0%	+6.7%
Q2 25	67M	+39.6%	+48.4%
Q3 25	67M	+0.5%	+42.7%
Q4 25	67M	-0.1%	+40.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$3.2K	23
Q2 22	$4.0K	23
Q3 22	$4.0K	23
Q4 22	$4.9K	26
Q1 23	$3.2K	26
Q2 23	$4.2K	26
Q3 23	$5.4K	26
Q4 23	$4.9K	32
Q1 24	$6.4K	32
Q2 24	$5.1K	32
Q3 24	$5.2K	32
Q4 24	$4.6K	33
Q1 25	$3.3K	33
Q2 25	$3.7K	33
Q3 25	$3.6K	33
Q4 25	$7.8K	31

Revenue / Employee